278results about How to "Substance reduction" patented technology

A resist composition for immersion exposure, including a base component (A) that exhibits changed solubility in an alkali developing solution under action of acid, an acid generator component (B) that generates acid upon exposure, and a fluorine-containing compound (C) represented by a general formula (c-1) shown below that is decomposable in an alkali developing solution:wherein R1 represents an organic group which may contain a polymerizable group, with the proviso that said polymerizable group has a carbon-carbon multiple bond, and the carbon atoms forming the multiple bond are not directly bonded to the carbon atom within the —C(═O)— group in general formula (c-1); and R2 represents an organic group having a fluorine atom.

A pharmaceutical paste composition comprising an active ingredient such as an addictive substance, a controlled release agent, and a pharmaceutically suitable aqueous or non-aqueous carrier. The composition may comprise one or more of a clay, or an oily, waxy, or fatty substance. The composition may be filled into a capsule or other dispensing device. The composition may reduce dose dumping of an active ingredient. Methods of making and using the composition are also described.

The present invention relates to dialysis solutions for peritoneal dialysis, containing hydroxyethyl starch as the osmotically-active substance, electrolytes and, optionally, conventional additives, where the hydroxyethyl starch has a molecular weight Mw in the range from 10,000 to 150,000, a substitution MS in the range from 0.10 to 0.40, a substitution DS in the range from 0.09 to 0.35 and a substitution ratio C2 / C6>=8. With this peritoneal dialysis solution it is possible, with an outstanding ultrafiltration, to maintain a longer dwell time, for example the dialysis solution can be utilized for a period of 12 hours in the CAPD without replacement. In addition, the inventive dialysis solution is also particularly advantageous for patients with residual kidney function. The resorption of the osmotically active substance is clearly diminished and even after a dwell time of 12 hours it amounts to a maximum of 60-70%.

A positive resist composition including a base component, an acid-generator component and a fluorine-containing polymer component (F) in a specific amount, the fluorine-containing polymer component (F) including a fluorine-containing polymer (F1) consisting of a structural unit (F-1) represented by general formula (F-1) (RC represents a hydrogen atom or a methyl group, R1 and R2 represent a hydrogen atom, an alkyl group or a fluorinated alkyl group, R3 represents a fluorine atom or a fluorinated alkyl group, and R4 represents an alkyl group or a fluorinated alkyl group) or a fluorine-containing copolymer (F2) containing the structural unit (F-1) and at least one structural unit selected from the group consisting of a structural unit (F-2) derived from an acrylate ester containing an acid dissociable, dissolution inhibiting group and a structural unit (F-3) represented by general formula (F-3) (RC represents a hydrogen atom or a methyl group, Z represents a single bond or a divalent linking group, and r represents an integer of 0 to 2).

A positive resist composition including a polymeric compound (A1) having a structural unit (a0) represented by general formula (a0-1) (R represents a hydrogen atom, an alkyl group of 1 to 5 carbon atoms or a halogenated alkyl group of 1 to 5 carbon atoms, R2 represents a divalent linking group, R3 represents a cyclic group containing —SO2— within the ring skeleton thereof) and a structural unit (a1) derived from an acrylate ester containing an acid dissociable, dissolution inhibiting group, an acid-generator component (B) and a fluorine-containing polymeric compound (F1) having a structural unit containing a base dissociable group.

A fluorine-containing polymeric compound which contains a structural unit (f1) that is decomposable in an alkali developing solution as a block copolymer portion, a base component (A) that exhibits increased solubility in an alkali developing solution under the action of acid, and an acid generator component (B) that generates acid upon exposure.

An integrated and modular air and lighting plenum that is the primary directional lighting mounting apparatus and laminar flow diffuser of an HVAC system in a healthcare setting. The plenum provides laminar air flow from the ceiling to the room in which it is located in accordance with HVAC requirements for healthcare environment settings, by using a plurality of cylindrical airflow outlets. The use of cylindrical airflow outlets promotes laminar airflow by reducing sharp boundaries that induce turbulence (e.g., the corners of rectangular or square outlets) and creates a highly sterile environment around the patient and staff in the operating room. The surgical lights used in the integrated air and lighting plenum allow the beam direction, spot size, focal point, brightness, and color temperature of the emitted light to be controlled.

A control apparatus for controlling an object that is modeled using at least one model parameter is provided. The control apparatus comprises an identifier, a controller and a modulator. The identifier identifies the model parameter. The controller is coupled to the identifier and uses the model parameter to determine a reference input so that an output of the object converges to a desired value. The modulator is coupled to the controller and applies any one of a delta-sigma modulation algorithm, a sigma-delta modulation algorithm and a delta modulation algorithm to the reference input to determine an input into the object. The model parameter is identified based on the output of the object and the reference input. Since the identifier determines the model parameter based on the reference input, the model parameters is prevented from vibrating.

A power semiconductor module and an inverter apparatus in which a device or a joining part is not mechanically damaged even when the temperature in use becomes a high temperature in the range of 175 to 250° C., resulting in excellent reliability at high temperature retaining test and thermal cycling test. Low thermal expansion ceramic substrates are disposed above and below the device. A material having a coefficient of thermal expansion of 10 ppm / K or less is disposed between the ceramic substrates. In addition, an inorganic material having a coefficient of thermal expansion in the range of 2 to 6 ppm / K or less is disposed around the device.

According to the invention, a fluorination treated substance remarkably reduced in the light absorption loss of a substance to be treated, such as a fluoride thin film, a fluorination treatment apparatus capable of producing the fluorination treated substance, and a process for producing a fluorination treated substance can be provided. Disclosed is a process for producing a fluorination treated substance, comprising an enclosure step of enclosing a substance to be treated in a reactor and a fluorination reaction step of introducing a fluorine gas into the reactor to bring the substance to be treated into contact with the fluorine gas and thereby carry out fluorination reaction.

The invention belongs to the technical field of medicaments, and relates to TS-1 granules for treating advanced gastric cancer and a preparation method thereof. The method comprises the following steps of: preparing active medicaments tegafur, gimeracil and potassium oxonate into a cyclodextrin inclusion compound; and sieving the inclusion compound, uniformly mixing the sieved inclusion compound and pharmaceutically acceptable auxiliary materials and performing wet granulation or dry granulation to prepare the granules. The granules have the advantages of increasing the water solubility and stability of the medicaments, covering the bitter taste of the tegafur, prolonging the action time, improving the medication compliance of patients with cancer, greatly improving the bioavailability of the medicaments and reducing the toxic or side effect of the medicaments.

Pigmented inks are disclosed comprising an aqueous medium, a pigment, a dispersant, and a humectant. Inks are disclosed where the humectant is a sulfonated polyethylene oxide which provides long decap times and fast drying of the printed image. Inks are further disclosed where the dispersant is an alkyl(sulfophenoxy)benzenesulfonic acid or its salt. Such dispersants reduce the agglomeration of pigment particles and reduce or eliminate the deposition of foreign substances on heater elements during the jetting process. A variety of pigments, dispersants, humectants, and aqueous media can be used. Combinations of a sulfonated polyethylene oxide humectant and an alkyl(sulfophenoxy)benzenesulfonic acid (salt) dispersant provide inks with good stability, few kogation problems, long decap times and relatively fast drying times.

The invention relates to a gemcitabine hydrochloride lyophilized powder injection and a preparation method thereof. The lyophilized powder injection comprises the following components in parts by weight: 20-30 parts of gemcitabine hydrochloride, 5-9 parts of mannitol, and 3-10 parts of sodium acetate. The freeze-drying step includes the following three stages: a pre-freezing stage, a primary drying stage and a secondary drying stage, and the entire freeze-drying time is lower than 20 hours. The gemcitabine hydrochloride lyophilized powder injection provided by the invention has the advantages of less types and amounts of adjuvants, easily-controlled technological parameters, simple process route, short freeze-drying time, convenience in operation, good repeatability, low contents of related substances, and controllable quality; and the redissolved lyophilized powder injection has good clarity and forming performance. The lyophilized powder injection has stable and controllable quality, is easy to realize industrial production, and can generate considerable economic and social benefits.

A process for the preparation of free carboxylic acids including: A) preparation of carboxylic acid by a biological cell located in an aqueous medium with addition of an amine of formula (I)where R1, R2 and R3, independently of one another, are identical or different, branched or unbranched, optionally substituted hydrocarbon radicals or H; B) for cases where the added amine A) is water-soluble, addition of a water-insoluble amine of formula (I), where, in A) or B), a multiphase system is obtained and the corresponding ammonium carboxylate is formed from the water-insoluble amine and the carboxylic acid; C) removal of the water-insoluble phase; and D) heating of the water-insoluble phase with release of free carboxylic acid.

The present invention provides a method of treating biomass that reduces water-polluting substances, suppresses the production of malodorous gases and greenhouse gases, decreases the nitrogen content in the compost or livestock bedding thus prepared, and furthermore, easily treats nitrogen-containing biomass in a short time at high temperature. The present invention also provides compost and livestock bedding produced by the method and a biomass treating agent. The method of treating biomass includes blending, with nitrogen-containing biomass, a Geobacillus microorganism having denitrification capability and a fermentation promoter that promotes the fermentation of the nitrogen-containing biomass by the Geobacillus microorganism.

An internal combustion engine control device includes a NOx adsorber catalyst disposed in an exhaust passage, an EGR passage, a reducing agent adding device, a torque fluctuation reducing device, and a fuel injection device. The EGR passage draws a portion of exhaust gas from the exhaust passage downstream of the NOx adsorber catalyst and recirculates the exhaust gas into the intake passage. The reducing agent adding device adds a reducing agent to exhaust gas upstream of the NOx adsorber catalyst to reduce substances adsorbed by the NOx adsorber catalyst. When or after the reducing agent adding device adds the reducing agent, the torque fluctuation reducing device advances the timing of the fuel injection device or carries out a pilot injection to reduce a fluctuation in engine torque. The reducing agent adding device adds less reducing agent while the torque fluctuation reducing device is operating.

A vibrating gyro device includes a piezoelectric substrate, an upper main surface electrode, a lower main surface electrode, and a support substrate. The piezoelectric substrate is provided with inner open holes and outer open holes. Side edge surfaces of a frame-shaped region in the X-Y plane are exposed to the interior of the frame through the inner open holes. Side edge surfaces of the frame-shaped region are exposed to the exterior of the frame through the outer open holes. Drive detection electrodes arranged within the upper main surface electrode are bonded to the upper main surface of the frame-shaped region and together with the lower main surface electrode are electromechanically coupled with deformation of the frame-shaped region in the Z-axis direction and deformation of the frame-shaped region in a direction parallel or substantially parallel to the X-Y plane. The support substrate provides a vibration space for the frame-shaped region and supports the piezoelectric substrate. The vibration space prevents interference between the frame-shaped region and the support substrate and connects the inner open holes and the outer open holes.

The invention relates to a pantoprazole sodium freeze-dried powder injection and a preparation method thereof. The powder injection is prepared from pantoprazole sodium and mannitol, wherein the consumption ratio of the pantoprazole sodium to the mannitol is (1:0.8)-(1:1.6), and the PH value is 10.5-11.0. In the invention, by lowering the pre-freezing temperature, properly lowering the freezing temperature, maintaining the lowered freezing temperature for a proper time, properly shortening two-stage drying time and carrying out other adjustment processes, good appearance and quality of the product can be kept under the condition that the content of the mannitol is low, the processes are reliable and feasible, and the effect is obvious. The prepared product has low content of related substances and has controllable quality, and the freeze-dried product has good clarity and formability after being redissolved.

Biologically inhibiting material presenting a surface with separated areas of anode material and cathode material, where the distance between any point on the active surface and both the adjacent cathode material and the adjacent anode material does not exceed 200 μm, as well as a method of producing said material. The material inhibits live cells coming into contact with or close to the material.

The invention relates to an Edaravone crystal form and a preparation method thereof. The Edaravone crystal form is characterized by X-ray diffractogram of powder. The crystal form can obviously improve the water solubility of Edaravone, thereby being more beneficial to preparation of injections. Besides, related substances are further decreased, and the safety of the preparation is improved.

The invention belongs to the technical field of pharmaceutical compounds, and relates to a pantoprazole sodium compound entity, especially a pantoprazole sodium crystal form, preparation methods and pharmaceutical preparations thereof. The pantoprazole sodium compound is crystal, and measured by X-diffraction powder diffraction, and the diffraction pattern has the following diffraction angles (2Theta) in turn: 9.5 degrees, 10.4 degrees, 11.6 degrees, 13.1 degrees, 13.8 degrees, 14.2 degrees, 15.0 degrees, 15.3 degrees, 15.9 degrees, 16.5 degrees, 17.5 degrees, 18.0 degrees and 18.2 degrees. The pantoprazole sodium compound entity may be associated with a variety of lyophilization supporting agents and the prepared lyophilized powder for injection has good solubility, good clarity and low content of related substances, etc. simultaneously the use level of the used lyophilization supporting agent is relatively less, the cost of the products is reduced, and the stability and quality of the products are improved.

A freze-dried Zuoximengdan for treating heart failure is prepared from the pharmacologically acceptable pH regulator and water-soluble precipient, and the solution of Zuoximengdan or its pharmacologically acceptable salt through freeze drying. Its advantage is high stability.

The present invention provides liposome-containing drug administration carriers that have improved residence time in the blood and improved migration into tumor cells as compared with conventional ones and that have reduced accumulation in the heart, and a pharmaceutical composition for treating a cancer that includes liposomes containing an antitumor active substance and having polyalkylene glycol and albumin bound thereto and that can be incorporated in large amounts in the cancer cells.

Disclosed is a cigarette use biological addition agent and use thereof, wherein the biological enzyme comprises degraded proteinase, amylase, pectic enzyme, polysaccharide degraded enzyme, cellulose, surface active agent, enzyme activating agent, wall material, emulsifying agent, and cushioning liquid. The preparing process comprises the steps of agitating, immobilizing, and utilizing addition agent.

The invention provides a preparation process of expanded stem products and belongs to the technical field of tobaccos. The preparation process comprises the following steps of: removing impurities such as metal, hemp ropes, stem heads and stem picks in tobacco stems; expanding the tobacco stems by microwave and steam; conveying the expanded tobacco stems into a pressure container to carry out pressure treatment; carrying out moisture regaining on the tobacco stems after pressure treatment and preparing into a certain product form; adopting a soaking mode to wash the stems, then dewatering by a physical mode till the water content is below 70%, and then adding additive feed liquid extracted from the tobaccos; adopting the traditional equipment in the tobacco industry to dry the stem products added with the feed liquid till the water content is 11 to 12%, adopting a flavoring machine to carry out flavoring treatment on the dried stem products, and balancing the water content to 11 to 12%. The preparation process provided by the invention has the advantages that the whole process is simple, the energy consumption is low, the quality of the expanded stem products obtained is close to that of the shredded tobacco product, the filling value is high, and large-scale adding can be achieved, so that the expanded stem product is an excellent tobacco additive.

There is provided a multilayer ceramic electronic component, including: a ceramic sintered body having a plurality of dielectric layers laminated therein; first and second capacitance portions being formed on surfaces of the dielectric layers; first and second lead-out portions being respectively extended from both sides of the first and second capacitance portions to be respectively exposed through both side surfaces of the ceramic sintered body and spaced apart from each other; sealing parts enclosing both end portions and corner portions of the ceramic sintered body; and first and second external electrodes enclosing the sealing parts and formed on both end portions of the ceramic sintered body to be electrically connected to the first and second lead-out portions, respectively.

The invention relates to the field of medicinal preparations, in particular to a taxol nanosuspension and a preparation method thereof. The taxol nanosuspension is characterized in that: a surfactant consists of poloxamer 188 and polyethylene glycol in a weight ratio of 1:1-1:3. According to the invention, the defects of low medicament loading rate, strong toxic or side effect, low stability, complex preparation process, high cost and the like in the conventional taxol preparation are overcome, and the technical breakthrough in the field is achieved; and the taxol nanosuspension has the advantages of increasing medicament content, reducing administration toxicity and production cost and improving the adaptability and compliance of a patient so as to realize clinical use.

A resist composition for immersion exposure including: a fluorine-containing polymeric compound (F) containing a structural unit (f1) having a base dissociable group and a structural unit (f2) represented by general formula (f2-1) (wherein R represents a hydrogen atom, a lower alkyl group or a halogenated lower alkyl group; and W is a group represented by any one of general formulas (w-1) to (w-4)); a base component (A) that exhibits changed solubility in an alkali developing solution under the action of acid; and an acid generator component (B) that generates acid upon exposure.

The present invention relates to the application of enzyme engineering technology in food production industry. The present invention prepares mixed pumpkin juice by means of composite enzyme system liquefying technology and enzymolysis terminal controlling technology. The enzymolysis reaction is one of adding composite enzyme system comprising cellulase, pectase and amylase into pumpkin juice, and the enzymolysis terminal is controlled via the viscosity and turbidity of enzymolyzed pumpkin juice. The present invention has the advantages of scientific and reasonable technological process, convenient operation, high pumpkin juice yield, high quality and stable color and turbidity.